ProMIS Neurosciences (PMN) - 2025 Q3 - Quarterly Results

Exhibit 99.1 ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights Phase 1b trial in Alzheimer's disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolled On track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026 Cambridge, Massachusetts – November 12, 2025 ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfold ...